Generic Name and Formulations:
Tretinoin 0.025%; crm; gel.
Indications for AVITA:
Apply sparingly to cleansed and completely dry skin once daily at bedtime. If irritation develops, may reduce the dosing frequency.
Not for use in eczema or on sunburned skin. Minimize exposure to sun, UV light, weather extremes. Avoid eyes, mouth, angles of nose, mucous membranes. Pregnancy (Cat.C): not recommended. Nursing mothers.
Allow effects of benzoyl peroxide, sulfur, resorcinol, salicylic acid, other topical acne agents to subside before applying. Avoid keratolytics, abrasives, astringents, drying agents, high-alcohol content topical products, spices, lime.
Apparent exacerbation of symptoms, local skin reactions (including erythema, edema, blistering, crusting), transient pigmentation changes, stinging on application, dry skin.
Crm, gel—20g, 45g
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma